Literature DB >> 15246207

Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy.

Manuel Romero-Gómez1, Rosa Ramos-Guerrero, Lourdes Grande, Laura Collantes de Terán, Raquel Corpas, Inés Camacho, Juan D Bautista.   

Abstract

BACKGROUND/AIMS: We performed the current study to assess the intestinal activity of enterocyte phosphate-activated glutaminase (PAG) in cirrhosis.
METHODS: Forty-nine cirrhotic patients and 36 control subjects underwent endoscopic duodenal biopsies. Minimal hepatic encephalopathy (MHE) was evaluated using three psychometric tests. Oral glutamine challenge (OGC) was performed and MELD, Child-Pugh and the presence of esophageal varices were recorded. PAG was measured by enzymatic methods. Cerebral magnetic resonance spectroscopy was performed in 10 cirrhotics.
RESULTS: PAG was found to be higher in cirrhotics than control subjects 2.4+/-1.51 vs. 0.68+/-0.57IU/mg protein (P<0.001). PAG was also increased in patients with MHE and correlated with MELD, INR, esophageal varices and serum bile acids. A negative correlation was observed between PAG activity and intra-cerebral choline/creatine ratio (r=-0.67; P=0.035) and a positive correlation with glutamine plus glutamate/creatine ratio (r=0.78; P=0.007). In multivariate analysis using backward logistic regression, presence of MHE was the only variable independently related to altered enterocyte PAG.
CONCLUSIONS: Enterocyte PAG is increased in cirrhotic patients and correlates with MHE. These data support a possible role for intestinal glutaminase in the pathogenesis of hepatic encephalopathy (HE) and could be a new target for future therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246207     DOI: 10.1016/j.jhep.2004.03.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  28 in total

1.  The Treatment of Patients With Hepatic Encephalopathy: Review of the Latest Data from EASL 2010.

Authors:  Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

Review 2.  Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.

Authors:  Milan Holecek
Journal:  Metab Brain Dis       Date:  2013-08-31       Impact factor: 3.584

Review 3.  The treatment of hepatic encephalopathy.

Authors:  Marsha Y Morgan; A Blei; K Grüngreiff; R Jalan; G Kircheis; G Marchesini; O Riggio; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

4.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

5.  Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis.

Authors:  Manuel Romero-Gomez; Maria Jover; Daniel Diaz-Gomez; Laura-Collantes de Teran; Regina Rodrigo; Ines Camacho; Miriam Echevarria; Vicente Felipo; Juan-D Bautista
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

Review 6.  Mammalian glutaminase isozymes in brain.

Authors:  Javier Márquez; Carolina Cardona; José A Campos-Sandoval; Ana Peñalver; Marta Tosina; José M Matés; Mercedes Martín-Rufián
Journal:  Metab Brain Dis       Date:  2012-11-14       Impact factor: 3.584

7.  Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats.

Authors:  Lin Jia; Mei-Hua Zhang
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

Review 8.  New technologies - new insights into the pathogenesis of hepatic encephalopathy.

Authors:  Luisa Baker; Bernard Lanz; Fausto Andreola; Javier Ampuero; Anisha Wijeyesekera; Elaine Holmes; Nicolaas Deutz
Journal:  Metab Brain Dis       Date:  2016-09-30       Impact factor: 3.584

Review 9.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

Review 10.  Role of artificial liver support in hepatic encephalopathy.

Authors:  V Stadlbauer; G A K Wright; R Jalan
Journal:  Metab Brain Dis       Date:  2008-12-21       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.